Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Sanam Shahid,Kavitha Ramaswamy,Jessica Flynn,Audrey Mauguen,Karlo Perica,Jae H Park,Christopher J Forlenza,Neerav N Shukla,Peter G Steinherz,Steven P Margossian,Jaap Jan Boelens,Nancy A Kernan,Kevin J Curran

Transplantation and Cellular Therapy（2022）

Cited 16|Views22

No score

Abstract

•Bridging chemotherapy is used during the manufacture of cimeric antigen receptor T cells.•Grade ≥3 infection is greater in patients following ≥2 cycles of bridging therapy.•Overall survival is lower following ≥2 cycles of bridging therapy.•Pretreatment disease burden is not reduced with ≥2 cycles of bridging therapy.

Translated text

Key words

Tisagenlecleucel,B cell acute lymphoblastic leukemia,CAR T cell therapy,Immunotherapy,CD19 antigen,Bridging chemotherapy

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined